Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Metastatic cancer
Stage/Subtype:  brain metastases
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 49 for your search:
Start Over
Stereotactic Radiosurgery Compared to Observation in Treating Patients with Brain Metastases
Phase: Phase III
Type: Treatment
Age: 3 and over
Trial IDs: 2009-0381, NCI-2011-00542, NCT00950001
Stereotactic Radiosurgery or Whole-Brain Radiation Therapy in Treating Patients with Brain Metastases That Have Been Removed by Surgery
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: N107C, NCI-2011-02676, CDR0000701474, NCCTG-N107C, NCT01372774
Stereotactic Radiosurgery or Whole Brain Radiation Therapy in Treating Patients with Newly Diagnosed Non-melanoma Brain Metastases
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 2011-0884, NCI-2014-02058, NCI-2012-00850, NCT01592968
TPI 287 in Treating Patients with Brain Metastases from Breast Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2010-0198, NCI-2011-00929, NCT01332630
Stereotactic Radiosurgery in Treating Patients with Large Brain Metastases
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 8312, NCI-2013-00845, CASE8312, NCT01843413
Radiosurgery Before Surgery in Treating Patients with Brain Metastases That Can be Removed by Surgery
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CASE 7312, NCI-2013-00644, NCT01891318
Nab-Paclitaxel, Temozolomide, and Bevacizumab in Treating Patients with Stage III-IV Melanoma with Brain Metastases That Cannot Be Removed by Surgery
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 1312169092, NCI-2015-00228, AX-MEL-PI-0019, ML29079, NCI-2015-00145, NCT02065466
Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: KD019-204, NCI-2014-02048, NCT02154529
Everolimus, Trastuzumab, and Vinorelbine Tartrate in Treating Patients With Progressive HER2-Positive Breast Cancer and Brain Metastases
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 21 and over
Trial IDs: LCCC 1025, NCI-2013-01079, 11-0242, NCT01305941
Neratinib, Capecitabine, and Trastuzumab in Treating Patients with HER2-Positive Breast Cancer That Has Spread to the Brain
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 11-344, NCI-2012-00255, TBCRC 022, NCT01494662
Tumor-Infiltrating Lymphocytes and High-Dose Aldesleukin after Combination Chemotherapy in Treating Patients with Metastatic or Locally Advanced Refractory Human Papilloma Virus-Associated Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 12-C-0116, NCI-2013-01524, 120116, 12C0116-H, 327146, P11943, NCT01585428
Whole-Brain Radiation Therapy with or without Lapatinib Ditosylate in Treating Patients with Brain Metastasis from HER2-Positive Breast Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: RTOG 1119, NCI-2012-01977, CDR0000735353, NCT01622868
Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer and High Dose Aldesleukin in Treating Patients With Metastatic Melanoma
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: MCC #16992, NCI-2012-01379, NCT01659151
Dabrafenib and Stereotactic Radiosurgery in Treating Patients With Melanoma and Brain Metastases
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: CC # 12857, NCI-2012-02214, NCT01721603
Bevacizumab in Pats w/ Recurrent ST Brain Metas who have Failed Whole Brain Radiation Therapy
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: NU 12C06, NCI-2013-00448, STU00080404, NCT01898130
Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 116521, NCI-2014-01364, NCT01978236
Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 117277, NCI-2014-01207, NCT02039947
Dacomitinib in Treating Patients with Progressive Brain Metastases
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: UCSD 130418, NCI-2014-00818, 130418, DP01-WS2043189, NCT02047747
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: ANG1005-CLN-04, NCI-2014-00443, NCT02048059
PET-Adjusted Intensity Modulated Radiation Therapy and Combination Chemotherapy in Treating Patients with Stage II-IV Non-small Cell Lung Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2013-252, NCI-2014-00216, NCT02073968
Ipilimumab Induction in Treating Patients with Melanoma Metastatic to the Brain Undergoing Stereotactic Radiosurgery
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: UMCC 2013.114, NCI-2014-01215, 2013.114, HUM00082134, NCT02097732
Stereotactic Radiosurgery and Ipilimumab in Treating Patients With Metastatic Melanoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: OSU-12182, NCI-2014-00381, CA184-236, NCT02107755
Cabozantinib S-malate with or without Trastuzumab in Treating Patients with Breast Cancer and Brain Metastases
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 14-359, NCI-2014-02365, NCT02260531
A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer That Has Spread to the Brain
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15450, NCI-2015-00514, I3Y-MC-JPBO, NCT02308020
Start Over